Goldman Sachs says it’s time for investors to put their money in Rhythm Pharmaceuticals as shares can rally nearly 40% with the success of its obesity medicine. “We believe that the outlook for Imcivree was transformed by initial [phase 2] data in patients with Hypothalamic Obesity (HO), which points to a high probability of clinical success in this indication where we also see a meaningfully higher peak sales opportunity as compared to other indications where Imcivree is in development,” analyst Corinne Jenkins wrote in a note to clients as she upgraded share to buy from a neutral rating. Hypothalamic obesity refers to weight gain that happens after injury to the hypothalamus, a critical part of the brain. Although shares have rallied more than 320% since the release of the data, Jenkins sees further upside to the stock should Rhythm continue to succeed in clinical trials and in its…
Create an account
Welcome! Register for an account
A password will be e-mailed to you.
Password recovery
Recover your password
A password will be e-mailed to you.
